Prague Med. Rep. 2026, 127, 145-150
Resmetirom: A New FDA-approved Drug as a Targeted Therapeutic Strategy in Metabolic Dysfunction Associated Steatohepatitis: Translational Evidence from Current Clinical Trials
, Malka A. Hassan4, Tushar Kanti Bhadra5
1Bahria University Health Science, Karachi, Pakistan
2Aga Khan University Hospitals, Karachi, Pakistan
3Allied Hospital, Faisalabad Medical University, Faisalabad, Pakistan
4Faculty of Medicine, Alexandria University, Alexandria, Egypt
5Dhaka Medical College, Dhaka, Bangladesh
Received May 21, 2025
Accepted September 8, 2026
Metabolic dysfunction-associated steatohepatitis (MASH) represents a significant global health burden, affecting 3–5% of the population and projected to become a leading cause of liver transplantation by 2030. This review examines Resmetirom, the first FDA-approved drug for non-cirrhotic MASH with moderate to severe hepatic fibrosis. As a selective thyroid hormone receptor beta (THR-β) agonist, Resmetirom enhances hepatic lipid metabolism through increased mitochondrial β-oxidation and improved lipoprotein profiles. Multiple clinical trials have demonstrated its efficacy in reducing hepatic fat content, improving liver histology, and resolving MASH without worsening fibrosis. While generally well-tolerated, gastrointestinal side effects including diarrhea and nausea were more common with Resmetirom than placebo. This breakthrough therapy offers a promising option for MASH management, though long-term studies and broader geographic representation in trials remain necessary to fully establish its role in clinical practice.
References
Copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
